Attendee search 

Single cell research has been identified as essential to the discovery of effective new drugs. Our team at ARL Designs has developed the Nano-Droplet Array Plate, an entirely new approach that satisfies this unmet need for isolating and studying individual cells over time.  Key to the proven success of this technology is our unique surface structure which causes nano-droplets to self-align and entrap individual cells at precise locations in large, high-density arrays.  Low fabrication costs will help drive this technology into the rapidly expanding market for 3D cell culture.

MEBIAS holds a game-changing platform to discover next generation, pathway-selective GPCR drugs devoid of on-target side effects once thought to be unavoidable.

Summary

Assets

  • Fully validated in vitro and ex vivo assay suite correlating ligand-induced dynamic conformation of GPCR to pathway-specific signaling

  • Differentiated mu-opioid receptor pre-development candidates for the treatment of pain, plus backup molecules

Business Proposal

MEBIAS seeks capital to establish a NewCo:

  • To co-develop our mu-opioid drug candidate

  • To fund lead discovery of additional targets

Team

Shariff Bayoumy – Unique expertise in GPCR expression and purification; former head of Janssen gene‑to‑protein team on soluble and membrane proteins

Lawrence Kuo – Former head, Structural Biology (Janssen); former head, Enzymology and Structural Biology (Merck); core member of project teams for Crixivan™ and Stocrin™

Brett A. Tounge – Extensive expertise in designing drug like small molecules from hit discovery through NME declaration; former head of Janssen NMR team

Customer Problem

G-protein coupled receptor (GPCR) therapeutics exhibit significant on-target adverse effects that can be alleviated by developing pathway-selective/biased drugs. The clinical benefit to dial pathway selectivity into future GPCR drugs has been clearly established, but current discovery approaches in the pharma/biotech industry are inadequate to speedily design and develop biased drugs.

Target Market

With the downsizing of internal R&D in the pharma industry, there is a dire need for new discovery platforms and assets to help fill early pipelines. GPCR therapeutics comprise ~30% of current prescribed drugs with a global market of >USD100 billion and a projected growth of 20% by 2018.

Customer

Our immediate targeted customers will be pharma and biotech R&D. Our intention is to co-develop GPCR pathway-selective drugs to treat CNS, Metabolic, and Inflammatory related disorders. The pathway-selective GPCR landscape is wide open.

Business Model

The first round of funding from investors will be used to form a NewCo with the specific goal to discover and progress pre-development candidates for pathway-selective GPCR indications. In hand we hold differentiated mu-opioid receptor pre-development candidates for the treatment of pain. Revenues from the sale or partnering of our pre-clinical assets will fund new R&D efforts.

Competitive Advantage

Additional players in the GPCR pathway selectivity space are highly desirable to help advance clinical need in numerous disease areas. Given our experience and access to two key technologies – native GPCR purification and protein nuclear magnetic resonance – our approach offers unique advantages lacking in current methodologies (that employ only cell-based assays).  We have demonstrated our competitive advantage by successfully delivering a series of mu‑opioid receptor compounds among which is an NME-stage compound.

- I-boxe: High-Tech Packaging for very High-value product transportation. A semi-active and smart box protected by two patents and created by a NASA engineer. - Igloo pouche: product for patient transportation drugs. A 2nd version is in the pipeline which would improve the easy and ready to use aspect

Sofrigam devises solutions to match the specific demands and requirements of laboratories, biotech, and the need to maintain heat-sensitive products at constant temperatures during transportation. Each year over $1Billion of drugs is fully secured thanks to its insulated solutions. Sofrigam supports companies to achieve their Total Cost of Ownership objectives.

Market segment 1: Biotech Market segment 2: Pharmaceuticals Diagnostics, vaccines and devices Market segment 3: Third-Party Logistics provider Market segment 4: High-value T

Advantage 1: TCO Mindset Advantage 2: Flexibility Advantage 3: Experience Advantage 4: Time-to-Market

Aderly Invest in Lyon is the economic development agency of Lyon - France

abCentral supports creation of innovative startup biotechnology companies by providing a world-class environment for entrepreneurs, and a fully functional life sciences laboratory within the Kendall Square innovation hub. We are next door to MIT, Novartis and Pfizer and close to many other large and medium-sized pharma companies, funding sources and academic institutions. We plan to be the premier laboratory facility for the next generation powerhouse biotech start-up. 

LabCentral creates an open, flexible environment for start-up life sciences companies: 
-Our architecture facilitates interaction and collaboration 
-Spaces are designed to spark discussion and encourage interaction 
-Ancillary services are offered to reduce the workload for startups 

To unclog the biotech start-up pipeline, an innovation hub must provide an awesome shared-lab space with business support services to create a fertile environment in which visionaries can thrive. We hope you will agree that LabCentral is that place.

Laboratory Services, RNAi, drug development, FDA, toxicology, probiotics, contract research laboratory, cell culture, nanotechnology, drug delivery, high throughput screening, IND, NDA, BSL-2, cancer biology